GSK × Relation Therapeutics
GSK and Relation Therapeutics announced a strategic research collaboration where Relation will generate large-scale perturbation datasets using advanced human cellular disease models. [48] The data will be used to train foundation models, including Relation's own MORGAN model, to deepen the understanding of disease biology. [48] Under the agreement, Relation may receive up to $110 million in upfront and success-based milestone payments, though the specific upfront amount was not disclosed. [48, 50]
The asset
A research collaboration focused on the generation of large-scale human cellular perturbation datasets to train and validate AI foundation models for drug discovery.
The record
- Seller status
- Going concern
- Sector
- AI drug discovery
- Modalities
- genomic data, multi-omics data, cellular perturbation data
- Jurisdiction
- UK
- Personal data
- Data is generated from physiologically relevant human disease models in a laboratory setting, not directly from patients in a clinical context for this deal. [48, 49]
What it means if you hold data
This deal highlights the increasing value of proprietary, high-quality biological data for training AI models in drug discovery. [46] Instead of licensing an existing AI platform, the buyer (GSK) is paying the seller (Relation) to manufacture the scarce underlying asset—the training data itself—signaling a strategic focus on controlling the foundational resource for AI in biology. [46]